Characterization of the Effects of Mesenchymal Stromal Cells on Mouse and Human Islet Function by Arzouni, Ahmed A. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1002/sctm.19-0023
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Arzouni, A. A., Vargas-Seymour, A., Dhadda, P. K., Rackham, C. L., Huang, G. C., Choudhary, P., ... Jones, P.
M. (2019). Characterization of the Effects of Mesenchymal Stromal Cells on Mouse and Human Islet Function.
Stem cells translational medicine, 8(9), 935-944. https://doi.org/10.1002/sctm.19-0023
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 09. Jul. 2020
Characterization of the Effects of Mesenchymal
Stromal Cells on Mouse and Human Islet
Function
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ABSTRACT
Islet transplantation has the potential to cure type 1 diabetes, but current transplantation pro-
tocols are not optimal and there is extensive loss of islet β-cell insulin secretory function dur-
ing the immediate post-transplantation period. Studies using experimental models of diabetes
have shown that the coculture of islets with mesenchymal stromal cells (MSCs) prior to trans-
plantation improves graft function, but several variables differed among research groups
(e.g., type of MSCs used and the treatment conditions). We have therefore assessed the
effects of MSCs on mouse and human islets by investigating the importance of tissue source
for MSCs, the coculture protocol configuration and length, the effect of activated MSCs, and
different β-cell secretory stimuli. MSCs derived from adipose tissue (aMSCs) were the most
effective at supporting β-cell insulin secretion in both mouse and human islets, in a direct con-
tact coculture configuration. Preculture with aMSCs enhanced both phases of glucose-induced
insulin secretion and further enhanced secretory responses to the non-nutrients carbachol and
arginine. These effects required a coculture period of 48–72 hours and were not dependent on
activation of the MSCs. Thus, direct contact coculture with autologous, adipose-derived MSCs for a
minimum of 48 hours before implantation is likely to be an effective addition to human islet trans-
plantation protocols. STEM CELLS TRANSLATIONAL MEDICINE 2019;00:1–10
SIGNIFICANCE STATEMENT
It is well established that mesenchymal stromal cells (MSCs) have beneficial effects on the func-
tional survival of islet grafts in experimental models of type 1 diabetes, and studies from differ-
ent groups have demonstrated that pretreating isolated islets with MSCs is sufficient to improve
graft function. However, these studies differ in the sources of MSCs, MSC/islet coculture proto-
col configuration and length, and other variables. The authors have therefore assessed the
importance of some of these variables in coculture of mouse and human islets with MSCs to
define how best to modify human islet transplantation protocols.
INTRODUCTION
Islet transplantation is gaining acceptance as a
therapy for type 1 diabetes (T1D), but current
protocols are not optimal [1]: there is exten-
sive loss of islet β-cell insulin secretory function
during the pretransplantation culture in vitro [1, 2]
and during the immediate post-transplantation
period, when islet function and survival are com-
promised by the hypoxic, inflammatory host envi-
ronment [3]. Mesenchymal stromal cells (MSCs)
offer the potential for improving the outcomes of
islet transplantation by exerting anti-inflammatory,
immunosuppressant, and regenerative effects
to protect the islet graft [4–7]. Several studies
have demonstrated that cotransplantation of
MSCs with islets has beneficial effects on graft
function to maintain normoglycemia in animal
models of T1D [8–12]. Some of these effects can
be attributed to MSCs influencing the host niche
to reduce inflammation [13–15], to suppress
acquired immune responses [4], and to enhance
graft revascularization [8, 16]. Moreover, in vitro
studies have demonstrated that MSCs also exert
direct effects on β-cells to enhance glucose-
induced insulin secretion [17–19] and to protect
them from inflammatory cytokine-induced apopto-
sis [20]. These effects can be attributed, at least in
part, to MSC-derived soluble mediators [20] and
extracellular matrix (ECM) [17] and may be
dependent on, or modified by, the activation of
MSCs by inflammatory cytokines [4, 5, 21]. Our
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previous studies in a mouse model of islet transplantation have
demonstrated that these effects on islet function in vitro trans-
late into improved glycemic control by the islet graft
in vivo [18–20].
These observations raise the possibility of improving trans-
plantation outcomes by pretreating the islet graft material
before implantation to ensure robust insulin secretion post-
transplantation. However, little attention has been paid to
define how best to pretreat islets with MSCs to maintain their
optimal function. In this study, we have assessed the func-
tional effects of coculturing mouse and human islets with
MSCs and have investigated the importance of MSC tissue
source, MSC/islet coculture configuration and length, MSC
activation, and the β-cell secretory stimulus.
METHODS
Islet Isolation and Culture
Mouse islets were isolated by collagenase digestion of mouse
pancreas followed by density gradient separation (as previously
described [22]), and maintained in culture (37C, 5% CO2) in
Roswell Park Memorial Institute (RPMI)-1640 (Sigma, UK) sup-
plemented with 10% (vol./vol.) fetal bovine serum (FBS; Gibco,
UK) and 1% (vol/vol) pen-strep. Human islets from ethically
approved and next of kin-consented cadaver pancreas donors
were supplied by the King’s College Hospital Human Islet Unit,
according to previously described protocols [17]. Islets (70%–85%
purity as assessed by dithizone staining [17]) isolated from four
donor pancreases were received within 48 hours of pancreas har-
vest from deceased donors.
Isolation and Characterization of MSC Populations
Mouse adipose and kidney MSCs (maMSCs and mkMSCs, res-
pectively) were isolated from male C57Bl/6 mice, character-
ized, and maintained in culture as adherent monolayers, as
previously described [17–19]. Human adipose and bone marrow
MSCs (haMSCs and hbmMSCs, respectively) were obtained from
commercial sources and maintained according to the suppliers’
instructions (Thermo Fisher Scientific R7788110 and Lonza PT-
2501, respectively). Human pancreatic (hp) MSCs were isolated
from pancreatic digest and characterized as previously described
for mouse MSCs [22]. Briefly, digest samples were pelleted
by centrifugation (1000g, 3 minutes), washed in phosphate-
buffered saline (PBS), resuspended in Dulbecco’s modified
Eagle’s medium (DMEM; Sigma) supplemented with 1% vol/vol
pen-strep, 10% vol/vol MSC-qualified FBS (Gibco 10500064),
seeded into 75 cm2 Nunclon tissue culture flasks, and incubated
at 37C, 5% CO2. Medium was changed after 24 hours to
remove nonadherent cells, and subsequently every 3 days to
enrich for an adherent cell population. Cells were subcultured
for a further three passages to enrich for adherent spindle-
shaped cells. These populations were characterized by in vitro
differentiation into osteoblasts, adipocytes, and chondroblasts
and by immunotyping by flow cytometry, as described previ-
ously [18, 19]. Figure 1A–1D shows trilineage differentiation of
hpMSCs maintained in osteogenic, chondrogenic, or adipogenic
supplements, and Figure 1E shows immunophenotyping of this
hpMSC population. The characterization of MSC populations
between passages 3 and 8 in our lab showed similar functional
phenotypes, so all cells used in this study were confined to this
range of passages.
Coculture of Islets and MSCs
MSCs (2 × 05 cells) were seeded into 35 mm Nunclon Petri dis-
hes, or six-well plates, and cultured as described above for
24 hours to form a confluent monolayer. For direct contact
islet-MSC coculture, 100 mouse or human islets were seeded
directly onto the MSC monolayers, and the culture medium
switched to RPMI-1640 (Sigma) supplemented with 10% (vol/vol)
FBS and 1% (vol/vol) pen-strep. For indirect contact coculture
conditions, inserts (1.0 μm pore, PET membrane, Falcon) were
placed into wells of a six-well plate preseeded with maMSCs,
and 100 mouse islets were cultured in the insert. The cocultures
were incubated for 72 hours at 37C, 5% CO2. In parallel, control
groups of 100 islets alone were incubated in noncoated 35 mm
petri dishes or culture inserts in RPMI-1640 medium. For all
experiments, islets were retrieved from the MSC monolayers or
Petri dishes by hand picking under a dissecting microscope.
Assessment of Islet Function In Vitro
Islets were harvested and assessed for glucose-stimulated
insulin secretion by static incubation in buffers supplemented
with 2 mM or 20 mM glucose [18, 19]. Briefly, islets were pre-
incubated for 2 hours in RPMI containing 2 mM glucose to
establish a basal rate of insulin secretion. Groups of three
islets were transferred into 1.5-ml microcentrifuge tubes and
incubated at 37C in a bicarbonate-buffered physiological salt
solution, supplemented with 2 mM CaCl2, 0.5 mg/ml BSA, and
either 2 or 20 mM glucose. Samples of the incubation medium
were taken after 1 hour and stored at −20C until assayed for
insulin content using an in-house radioimmunoassay [23]. Each
experimental treatment was tested on 10 separate groups of
islets, and experiments were repeated a minimum of 3 times
using different islet preparations. For measurements of islet
insulin content, groups of 10 islets were incubated for 24 hours
in acidified ethanol (52:17:1 absolute ethanol:H2O:conc. HCL) at
4C. In some experiments, a temperature-controlled (37C) mul-
tichannel perifusion system was used to determine the dynamic
pattern of insulin secretion [17]. Briefly, groups of 50 islets were
placed on 1 μm nylon filters in filter holders (Swinnex, Millipore,
Cork, Ireland) and perifused at a flow rate of 0.5 ml/min with
the physiological salt solution supplemented with insulin secre-
tagogues. Perifusate samples were collected every 2 minutes
and stored at −20C. Each experimental treatment was
tested on four separate groups of islets, and experiments were
repeated a minimum of three time using different islet
preparations.
Activation of MSCs
Activation of MSCs was achieved as described previously [4].
Briefly, 2 × 105 maMSCs were seeded into Nunclon 35 mm
Petri dishes in DMEM (plus supplements, as above) and allowed
to adhere for 24 hours. The medium was replaced by DMEM
supplemented with interferon-γ (INF−γ) and tumor necrosis
factor-α (TNF-α; Peprotech, London, United Kingdom; 20 ng/ml
each), and the maMSCs were incubated for further 8 hours.
MSCs were washed with PBS, trypsinized, and pelleted by cen-
trifugation (1000g, 3 minutes), and mRNA was extracted using a
commercially available kit (RNeasy mini kit, QIAGEN, United
Kingdom) The expression of mRNAs for chemokine (C-X-C motif)
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ligand 9 (CXCL9) and nitric oxide synthase (NOS2) was quanti-
fied against glyceraldehyde-3-phosphate dehydrogenase mRNA
by quantitative real-time polymerase chain reaction using QIAGEN
QuantiTect primers (QT0010124; QT00100275) as described previ-
ously [20].
Statistical Analysis
Differences between treatments were assessed initially using
two-way analysis of variance with post hoc testing using
Bonferroni or unpaired Student’s t test, as appropriate, and
considered significant when p < .05.
RESULTS
Effects of MSC Coculture on Islet Secretory Function
Initial experiments were performed to assess whether MSCs
isolated from different tissues had similar effects on islet
function and to determine whether mouse and human islets
responded in similar ways to coculture with MSCs. These
experiments used a direct contact coculture configuration and
an incubation time of 72 hours, parameters which we had
previously reported to enhance β-cell function by MSCs [17].
Figure 2A, 2B shows that coculture of mouse islets with maMSCs
or mkMSCs caused a significant increase in glucose (20 mM)-
induced insulin secretion when compared with untreated control
islets. In each of three separate experiments using different
mouse islet preparations, those which had been pretreated with
maMSCs secreted significantly (p < .01) more insulin in response
to 20 mM glucose than those pretreated with mkMSCs, reflected
by the different scaling of the y axes of the panels in Figure 2A,
2B. The increased insulin release from maMSC-pretreated islets
was not secondary to alterations in islet insulin content (con-
trol untreated, 43  3 ng insulin per islet; maMSC pretreated
36  6, n = 3, p > .2), as has been reported previously [17, 19].
Human MSCs exerted similar beneficial effects on glucose-
induced insulin secretion from human islets, as shown in
Figure 2C–2E. Isolated human islets are inherently more vari-
able than mouse islets in their insulin secretory responses to
glucose, but the effects of MSCs to enhance insulin secretion
in the presence of 20 mM glucose were observed in islets iso-
lated from four separate donors. Thus, MSCs isolated from
four different tissues had qualitatively similar effects on
glucose-induced insulin secretion when maintained in a direct
Figure 1. Characterization of human pancreatic mesenchymal stromal cells (MSCs). (A–D): Trilineage differentiation potential of human
pancreatic MSCs (pMSCs). Prior to differentiation human pMSCs displayed characteristic spindle-shaped morphology (A). Following
28 days treatment with osteogenic, chondrogenic, or adipogenic differentiation supplements, pMSCs demonstrated trilineage differentia-
tion potential in vitro. Alizarin red staining identified punctate mineral deposition across cell monolayers exposed to osteogenic medium
(B). Alcian blue staining detected glycosaminoglycan deposition within cell micromasses directed toward a chondrogenic fate (C). Oil Red
O staining detected the formation of lipid droplets in MSCs treated with adipogenic medium (D). Each image is representative of three
wells. Scale bar = 100 μm (A–C), 50 μm (D). (E): Immunophenotyping human pMSCs. Cultured human pMSCs were analyzed for expres-
sion of key cell surface markers by flow cytometry. Negative isotype-matched controls shown by light gray peaks, marker expression
shown by blue peaks. Cells highly expressed markers CD90, CD105, and CD73 (all >99%). Expression of CD14, CD20, CD34, and CD45,
markers of monocytes, B cells, and hematopoietic progenitors was absent.
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contact configuration; MSCs exerted beneficial effects on both
mouse and human islets; and adipose-derived MSCs were con-
sistently more effective, at least with mouse islets. Subsequent
experiments to further characterize islet-MSC interactions were
therefore focused on mouse islets and maMSCs.
Effect of Protocol Configuration on MSC-Islet
Interactions
We compared two commonly used protocol configurations for
studying MSC-islet interactions: direct contact, in which the
islets are cultured in suspension on top of an adherent MSC
Figure 2. Mesenchymal stromal cells enhance glucose-induced insulin secretion from mouse and human islets. Coculture (72 hours) with
(A) maMSCs (solid bars) or (B) mkMSCs (solid bars) significantly increased insulin secretion from mouse islets in response to a subsequent
exposure to 20 mM glucose when compared with untreated mouse islets (open bars). Similarly, coculture of human islets with (C)
haMSCs, (D) hbmMSCs, or (E) hpMSCs (solid bars) significantly enhanced glucose-induced insulin secretion compared with untreated
human islets (open bars). Graphs show one experiment typical of three or four separate experiments using different islet preparations.
Bars show means + SEM; n = 10; **, p < .01; ***, p < .001 versus untreated islets. Abbreviations: haMSCs, human adipose mesenchymal
stromal cells; hbmMSCs, human bone marrow mesenchymal stromal cells; hpMSCs, human pancreatic mesenchymal stromal cells;
maMSCs, mouse adipose mesenchymal stromal cells; mkMSCs, mouse kidney mesenchymal stromal cells.
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Figure 3. Time course of effects of mesenchymal stromal cell (MSC) coculture on glucose-induced insulin secretion. Insulin secretion by
mouse islets was measured at substimulatory (2 mM) and stimulatory (20 mM) glucose concentrations after coculture with maMSCs for
24, 48, or 72 hours, as shown by the key. Data are presented as mean + SEM, n = 10 observations in one experiment typical of three sep-
arate experiments using different islet preparations. ***, p < .001, versus non-MSC-treated islets controls at appropriate time points.
Abbreviation: maMSCs, mouse adipose mesenchymal stromal cells.
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monolayer, and indirect contact, in which the islets were sepa-
rated from the MSC monolayer by a porous membrane [24].
Figure 2A shows that direct contact between mouse islets and
maMSCs enhanced subsequent glucose-induced (20 mM) insu-
lin secretion. In contrast, indirect coculture experiments ran in
parallel showed no enhancement of glucose-induced insulin
secretion. Thus, in three separate experiments using different
mouse islet populations, indirect coculture had no significant
effect (p > .2) on basal (2 mM glucose) insulin secretion; no
significant effect (p > .2) on glucose-induced insulin secretion
in two experiments, and a significant inhibition (p < .01) of
glucose-induced insulin in one experiment (20 mM glucose:
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Figure 4. Activation of maMSCs. (A, B): Cytokine-induced activation of maMSCs. maMSCs were cultured in the absence or presence of
interferon-γ (20 ng/ml) and tumor necrosis factor-α (20 ng/ml) for 8 hours and NOS2 (A) and CXCL9 (B) mRNAs were measured 24, 48,
and 72 hours after the removal of cytokines. Data are expressed as mean + SEM, n = 3 in one experiment representative of three sepa-
rate experiments. **, p < .001; ND, not detectable. (C, D): Effects of islet coculture on maMSC activation. Quiescent or cytokine-activated
maMSCs were cocultured with mouse islets for 72 hours, followed by the measurement of NOS2 (C) and CXCL9 (D) mRNAs in the maMSC
populations. Data are expressed as mean + SD; n = 3 observations in one experiment representative of three separate experiments.
**, p < .01. (E): Effects of maMSC activation on glucose-stimulated insulin secretion from mouse islets. Insulin secretion at substimulatory
(2 mM) and stimulatory glucose concentration (20 mM) from islets alone (white bar), islets cocultured with maMSCs (black bar), and
islets cocultured with activated maMSCs (hatched bar). Data are presented as mean + SEM; n = 10 observations. ***, p < .001;
**, p < .01; *, p < .05. Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; maMSCs, mouse adipose mesenchymal stro-
mal cells; MSCs, mesenchymal stromal cells.
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MSC precultured islets 59%  5% controls, n = 10, p < .01).
Therefore, subsequent experiments were performed using the
direct contact coculture configuration.
Effect of MSC Coculture Length on Islet Secretory
Function
The effects of MSC coculture on mouse islet secretory function
were assessed by measuring basal (2 mM glucose)- or glucose
(20 mM)-induced insulin release after periods of 24, 48, or
72 hours. Figure 3 shows that coculture for 24 hours had no
significant effect on glucose-induced insulin secretion, whereas
significant increases were observed in islets maintained in
coculture with maMSCs for 48 or 72 hours, with no significant
differences between these time points. MSC coculture did not
significantly increase basal (2 mM glucose) insulin secretion
(p > .2). These effects were observed in three separate experi-
ments using different mouse islet populations. Thus, the effects
of MSCs on β-cell secretory function are relatively slow to
develop, requiring a minimum coculture period of 48 hours.
Effects of MSC Activation on MSC-Islet Interactions
Activation of MSCs by an inflammatory environment is associ-
ated with their adopting an anti-inflammatory phenotype
(MSC2 cells), as evidenced by the expression of CXCL9 and
NOS2 [4]. Under unstimulated conditions, the expression of
mRNAs for CXCL9 and NOS2 was undetectable in maMSCs. In
contrast, maMSCs incubated in vitro (8 hours) with the inflam-
matory cytokines INF-γ and TNF-α expressed high levels of
NOS2 and CXCL9 mRNAs (0.113  0.01 vs. 0.0001  5.543e-
005, 0.8  0.2 vs 0.0002  0.0002, respectively), which is
consistent with an activated profile. The cytokine-induced acti-
vation of maMSCs was maintained for at least 72 hours after
removal of the cytokines, as demonstrated by the maintained
levels of CXCL9 and NOS2 mRNA expression (Fig. 4A, 4B). The
coculture of islets with unstimulated maMSCs (72 hours) did
not influence their activation status, as assessed by NOS2 and
CXCL9 mRNA levels. However, coculturing islets with cytokine-
activated MSCs did cause a small, albeit significant, reduction
in the expression of both mRNAs (Fig. 4C, 4D). Cytokine-
induced activation of maMSCs had no effect on their ability
to enhance glucose-induced insulin secretion, as shown in
Figure 4E. Direct coculture of mouse islets with maMSCs signif-
icantly enhanced their subsequent insulin secretory responses
to 20 mM glucose, as previously observed (Figs. 2–3), but
there were no differences in basal (2 mM glucose) nor stimu-
lated (20 mM glucose) insulin secretion from islets cocultured
with unstimulated or activated maMSCs (Fig. 4E). Thus, the
beneficial effects of MSCs on β-cell insulin secretory function
are independent of their activation status.
Effects of MSCs on Insulin Secretion in Response to
Non-Nutrients
Islet β-cells use different mechanisms to recognize and respond
to nutrient and non-nutrient stimuli [25, 26]. Nevertheless, most
studies to date have focused solely on MSCs influencing β-cell
responses to glucose, the main nutrient secretagogue in mam-
mals. Here, we have investigated two non-nutrient secreta-
gogues, the nicotinic cholinergic receptor agonist carbachol, and
the amino acid arginine. Figure 5A shows that islets cocultured
with maMSCs show significantly enhanced insulin secretory
responses both to 20 mM glucose alone and to 20 mM glucose
in the presence of carbachol (500 μM). Figure 5B shows that
arginine (20 mM) was sufficient to stimulate insulin secretion at
basal glucose (2 mM) and that preculture with maMSCs signifi-
cantly increased insulin secretory responses to arginine alone
and to glucose alone (20 mM), as previously observed (Figs. 2–3).
Thus, coculture with MSCs enhances β-cell insulin secretory
responses to both nutrient and non-nutrient secretagogues.
Effects of MSCs on Biphasic Insulin Secretion
Glucose-induced insulin secretion shows a distinctive temporal
pattern, with a rapidly rising initial peak (first phase), followed
by a maintained plateau (second phase), with both phases
being regulated by different β-cell intracellular mechanisms
[27]. Dynamic measurements of insulin secretion from mouse
islets demonstrated that preculture with maMSCs enhanced
both phases of the secretory response to glucose (20 mM),
as shown in Figure 6A. Perifusion of the islets with a sub-
stimulatory concentration of glucose (2 mM) established a
low, stable rate of insulin secretion. Switching to a maximum
stimulatory concentration of glucose (20 mM) initiated a rapid
peak (2–4 minutes) in insulin secretion (first phase), followed
by a maintained elevation in insulin secretion in response to
20 mM glucose (second phase). Islets which had been cocultured
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Figure 5. Effect of mesenchymal stromal cells coculture on insu-
lin secretion in response to non-nutrients mouse islets were cul-
tured for 48 hours either alone (white bars) or with maMSCs
(black bars), followed by measurement of insulin secretion in
response to (A) 2 mM glucose, 20 mM glucose, and 20 mM
glucose + 500 μM carbachol; or (B) 2 mM glucose, 20 mM glucose,
and 20 mM arginine. Data are presented as increase in
insulin secretion over basal (2 mM glucose), mean + SEM; n = 10.
***, p < .001. Abbreviation: maMSCs, mouse adipose mesenchy-
mal stromal cells.
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with maMSCs secreted significantly more insulin throughout the
exposure to 20 mM glucose, indicating enhancement of both
first and second phases of the secretory responses. In a similar
experiment (Fig. 6B), the perifused islets were subsequently
exposed to carbachol in the presence of 20 mM glucose, which
further and substantially enhanced the insulin secretory
response to 20 mM glucose alone (note different y axes in
panels A and B). Islets which had been cocultured with
maMSCs secreted significantly more insulin throughout the
exposure to 20 mM glucose and to 20 mM glucose plus car-
bachol, confirming the enhancement of secretory responses
to both nutrient and non-nutrients (see Fig. 5).
DISCUSSION
There is accumulating evidence that MSCs can exert beneficial
effects on islet β-cell function and survival, thus improving the
outcomes of islet transplantation in experimental models of
T1D. The well-documented anti-inflammatory and immunosup-
pressant effects of MSCs are likely to improve graft survival
in vivo by modifying the host environment and in vitro studies
have also demonstrated direct effects of MSCs on islet β-cells
to improve their insulin secretory capacity [17, 19, 28] and to
protect them from apoptotic stimuli [20]. This raises the possi-
bility of enhancing islet graft functional survival by treating the
islets with MSCs before transplantation [24], so avoiding the
logistical, safety, and regulatory concerns of codelivering MSCs
in clinical islet transplantation protocols. To date, experimental
studies have used a range of different MSCs and in vitro cul-
ture conditions [8, 12, 20, 29, 30], but the effective translation
of these experimental observations into improved clinical pro-
tocols will require consensus about how best to use MSCs to
support graft function. In the current study, we have investi-
gated a number of parameters to optimize the beneficial
effects of in vitro coculture of islets with MSCs.
Our observations that MSCs derived from four different tis-
sues had similar qualitative effects to enhance insulin glucose-
induced secretion without affecting basal secretion suggest
that this is a general property of MSCs. Our measurements
showed that the MSC-dependent enhancement of insulin secre-
tion was not secondary to increased insulin content, confirming
previous observations in mouse [17, 19] and human [17] islets,
consistent with an upregulation of the β-cell secretory response
to elevated glucose, the most physiologically important initiator
of insulin secretion in mammals [27]. Importantly, our experi-
ments using human islets confirm and extend previous studies
[17, 19] to demonstrate that human MSCs from a variety of
Figure 6. Effect of mesenchymal stromal cells on dynamic insulin secretion from mouse islets. Mouse islets cultured for 48 hours either
alone (black, solid line) or with maMSCs (red, dotted line) were perifused with solutions containing (A) 2 or 20 mM glucose; or (B)
20 mM glucose + 500 μM carbachol. Points show mean  SEM; n = 4 observations in one experiment typical of three separate experi-
ments using different islet preparations. Abbreviation: maMSCs, mouse adipose mesenchymal stromal cells.
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tissues have the ability to enhance human β-cell function.
Human islets are much more variable than mouse islets, and
factors such as donor age, body mass index, and health status,
as well as duration of donor pancreas cold ischemia time, are
known to affect human islet function [31]. Nevertheless, the
available evidence confirms the potential benefits of incorporat-
ing MSCs into clinical islet transplantation protocols. The opti-
mal source of MSCs for clinical use in islet transplantation will
likely be a balance between functional phenotype and accessi-
bility. Bone marrow- and adipose-derived MSCs are commonly
used experimentally because of the accessibility of the tissues
for autologous grafts. Our early in vivo studies used kidney-
derived MSCs because mouse islets are commonly transplanted
below the kidney capsule [9, 18, 22], and pancreatic MSCs can
be derived from pancreatic digests used to isolate donor islets.
We suggest that autologous MSCs isolated and expanded from
host adipose biopsies may offer the simplest source in a clinical
setting.
Several different configurations have been used to facili-
tate islet-MSC interactions during coculture in vitro, including
direct contact of islets on an adherent monolayer of MSCs
[17, 28]; the formation of composites by suspension culture of
islets and MSCs [2, 8, 32]; and indirect coculture conditions,
where islets and MSCs are physically separated by porous bar-
riers to prevent contact but allow the diffusion of soluble
mediators [28]. In agreement with our study, direct contact
coculture of islets with MSCs has consistently been reported
to improve glucose-stimulated insulin secretion, whereas non-
contact coculture systems are more variable, with some reports
of enhanced insulin secretion [8, 33] and others of no effect
[18, 28, 34]. There is convincing evidence that at least some of
the beneficial effects of MSCs on β-cell function are mediated
via secreted molecules [17, 20, 35], which should be able to
access the islet cells in the indirect coculture systems. These
in vitro effects of MSC-derived molecules on islet function per-
sist for several days after treatment [35], and translate into
improved islet graft in vivo in a mouse model of diabetes, as
assessed by glycemic control [20, 35]. However, the diffusion
distances and consequent dilution of MSC-derived soluble medi-
ators in such configuration may prevent effective concentrations
reaching the islets, which may explain some of the reported
inconsistencies between studies [8, 18, 28, 33, 34]. The effec-
tiveness of direct contact coculture may also reflect the impor-
tance of interactions between islet cells and MSC-derived ECM
[17], which can influence β-cell function both via direct contact
and by acting as a local reservoir for biologically active MSC-
derived secretory products [24], thus maintaining their high
local concentrations in the vicinity of the islet cells. We suggest
that direct contact coculture of islets with MSCs prior to trans-
plantation is likely to be the most effective configuration for
improving human islet transplantation protocols.
Most studies which report the coculture of islets with
MSCs [18, 19, 22, 28] or with MSC-derived secretory products
[17, 20] use incubation periods greater than 48 hours, although
the rationale for this time frame is rarely justified. Our results
demonstrate that the effects of MSC on β-cell function are rela-
tively slow in onset, requiring 48–72 hours to develop fully. This
might seem unexpected, particularly for the effects mediated
by MSC-derived soluble molecules acting on β-cell surface
receptors [17, 20], but it may reflect the time required for MSCs
to generate sufficient ECM or effective local concentrations of
soluble mediators to influence β-cell function. Alternatively, the
onset of functional changes in the β-cells may require modifica-
tions in gene expression which can take time to manifest as
phenotypic changes. For example, it is well established that
interactions with ECM induce numerous modifications in the
expression of genes influencing β-cell survival, growth, and dif-
ferentiation [24, 36] and that MSC-derived secretory factors
modify gene expression in their target cells [37]. MSC-mediated
changes in β-cell gene expression is also consistent with the
sustained effects of MSC-derived secretory factors on β-cell
function in vitro, some of which were maintained for up to
72 hours after the removal of the factors from the culture
medium [35]. Irrespective of the underlying mechanisms, the
incorporation of MSC pretreatment into human islet transplan-
tation protocols will require a minimum of 48 hours coculture
period before implantation. The practice of centralized human
islet isolation facilities with distribution to remote transplanta-
tion centers, along with the requirement for pretransplantation
assessment of islet function and sterility, do allow for such a
coculture period.
Activation or “licensing” of MSCs is thought to be impor-
tant for their adopting an anti-inflammatory phenotype [4, 21,
38–40]. Our study confirms that in vitro exposure of MSCs to
inflammatory cytokines induces their prolonged activation but
coculture with islets was not alone sufficient to induce MSC
activation. These observations imply that activation of MSCs is
likely to be a property of the inflammatory host niche rather
than of the islet graft and most likely mediated by the innate
immune response to the graft. Delivery of islet grafts via the
clinically preferred intraportal route will expose them to both
the instant blood-mediated inflammatory response and to the
endogenous liver immune system [41], whose inflammatory
response to the graft may be exacerbated by the presence of
acinar tissue in the less pure human islet preparations [42].
Further studies are required to determine whether MSCs, acti-
vated or unactivated, exert protective effects on islets lodged
in the hepatic microvasculature. We also demonstrated
that MSC-mediated effects on β-cell secretory function were
independent of MSC activation. This is consistent with MSCs
influencing graft functional survival through two independent
mechanisms: direct effects on β-cell function, which do not
require MSC activation and improvement of the host niche by
reducing inflammation, which may require MSC activation.
Previous studies of MSCs and β-cell secretory function
have focused on their enhanced secretory responses to glu-
cose [18, 19, 43] [17, 28]. We demonstrate here that MSC
pretreatment also enhances insulin secretion in response to
non-nutrient and receptor-mediated agonists. The mechanisms
of glucose recognition by β-cells are well understood: glucose
and other nutrients initiate insulin secretion by increasing met-
abolic fluxes and ATP generation, leading to β-cell depolariza-
tion and Ca2+ influx through voltage-dependent Ca2+ channels,
which triggers the exocytotic release of insulin [27]. In con-
trast, carbachol and other receptor-mediated agonists do not
initiate insulin secretion but potentiate responses to nutrients
via well-characterized intracellular pathways [27], whereas the
cationic amino acid arginine is thought to stimulate insulin
secretion primarily by inducing depolarization upon its trans-
port into the β cell [44]. Our observation that MSC coculture
enhanced β-cell responses to all these stimuli suggests an
overall upregulation of the exocytotic process rather than
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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specific effects on signal recognition and intracellular transduc-
tion cascades. This is in accordance with the recent report that
coculture of human hepatocytes with MSCs enhanced their
secretion of albumin into the medium [45], a process which
occurs by constitutive exocytosis and is therefore independent
of signal recognition and stimulus-response coupling cascades.
Thus, MSC pretreatment may facilitate graft function in vivo
when β-cells are required to respond not only to glucose but
also to potentially hundreds of receptor-operated signals [46].
CONCLUSION
In summary, the results of this and other studies suggest that
coculture of islets with MSCs pretransplantation has the poten-
tial to improve overall graft insulin secretory function. Direct
contact coculture with autologous, adipose-derived MSCs for a
minimum of 48 hours before implantation is likely to be an
effective addition to human islet transplantation protocols.
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